• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

When SpaceX starts trading, some 'shareholders' will discover they own nothing at all

2

Corporate America has been draining the world's water. Matt Damon's new campaign calls on Gap, Starbucks, and Amazon to help give it back

3

Current price of oil as of June 12, 2026

1

When SpaceX starts trading, some 'shareholders' will discover they own nothing at all

2

Corporate America has been draining the world's water. Matt Damon's new campaign calls on Gap, Starbucks, and Amazon to help give it back

3

Current price of oil as of June 12, 2026
Healthobesity

Injectable weight-loss drugs like Wegovy are having a moment. This health care founder says it’s time that obesity—a chronic disease, not a character flaw—does, too

By
Erin Prater
Erin Prater
Down Arrow Button Icon
By
Erin Prater
Erin Prater
Down Arrow Button Icon
April 5, 2023, 4:27 PM ET
As weight-loss drugs make headlines, the topic of obesity is again at the forefront of the social consciousness.
As weight-loss drugs make headlines, the topic of obesity is again at the forefront of the social consciousness.Getty Images

Weight-loss medications like Wegovy and Saxenda are flying off pharmacy shelves, given their ability to shave nearly 20% off one’s body weight with a single weekly jab.

As the miracle drugs make headlines, the topic of obesity is again at the forefront of the social consciousness—and the debate that accompanies it. Is obesity hereditary? A choice? Influenced by other factors like poverty and mental illness?

And does it even matter?

“It’s my personal belief that even if someone chose a particular path—and I don’t think that’s the case here—once someone is suffering and sick, I think we, as a society, should treat them,” Zach Reitano says. He’s the cofounder and CEO of Ro, a health care company that treats conditions like obesity, hair loss, and erectile dysfunction via telehealth without requiring insurance. (Reitano will be speaking on the topic of overcoming obesity at Fortune Brainstorm Health later this month. To learn more about the conference, click here.)

The stunning success of Wegovy and similar drugs have created the opportunity for conversation about obesity and the factors behind it—and the list doesn’t include character flaws and moral failures, he says.

“Having obesity has often been thought of as a flaw of self-discipline or willpower,” Reitano says. “There are very few health care conditions where people know you have them from an initial interaction—and make a snapshot judgment as a result.”

Evidence is mounting that obesity is “more so a neurohormonal disease” than a consequence of lifestyle choices—“a medical condition similar to other chronic diseases we’re more familiar with, like diabetes and hypertension,” he says.

While genetic, environmental, and behavioral components all play into the development of obesity, behavior plays far less of a role than one might think, he contends.

The fact that the vast majority of those who go off Wegovy or similar drugs will regain the weight they lost demonstrates that obesity is, indeed, a chronic disease, he maintains—and we should think before judging someone experiencing rebound weight gain.

“If this were diabetes or hypertension or high cholesterol, when you go off a statin or blood pressure medication or stop taking insulin, you’d expect a negative result,” he says, adding that there’s no reason why we shouldn’t expect the same result in those who stop using the weight loss injectable.

Medications like Wegovy allow the body to defend a “set point, an ideal weight and level of body fat their body wants them to have.” Normally, when someone attempts to lose weight, their body transitions to a starvation response, which increases their appetite and sometimes even slows their metabolic rate—turning weight loss into a battle, Reitano says.

“Their body is constantly fighting them, mimicking the starvation response,” he adds. “To expect an individual to fight a starvation response for 80 years is extremely unreasonable.”

Drugs like Wegovy and Ozempic mimic a hormone produced in the intestines after meals, called glucagon-like peptide-1 (GLP-1). It helps regulate appetite and food intake, sending a signal to the brain that “prevents your body from initiating that starvation response,” and allowing one to be more satisfied with fewer calories. While Wegovy is approved for the treatment of obesity in those who have weight-related health conditions like high blood pressure or cholesterol, Ozempic is only approved for those with Type 2 diabetes.

Because obesity is a “chronic neurohormonal disease,” patients with it “need ongoing care,” Reitano says—and that may entail long-term use of medications like Wegovy.

“They’re not for everyone, but they can be a godsend, a game-changer for those for whom they’re clinically appropriate,” he says. “They aren’t replacements for other healthy activities,” or for diet and exercise. “But in many ways, they will actually assist like a jet pack, in terms of helping someone improve their behavior.

“It’s much easier to adhere to a diet if your body isn’t telling you you’re starving.”

Each year, Fortune Brainstorm Health assembles some of the best minds in health care to discuss the most pertinent topics in the industry. This year’s event, which takes place April 25–26 in Los Angeles, will feature conversations at the crossroads of health care, business, technology, and investing. 

One of our main stage sessions at the upcoming event will focus on innovations in the field of obesity and will include Reitano. Interested in applying to register for Brainstorm Health? Please click here for more information.

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.
About the Author
By Erin Prater
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

arms
HealthPsychology
You probably think you’re a really open-minded person, but the real thing raises your death anxiety
By Daryl Van Tongeren and The ConversationJune 12, 2026
17 hours ago
AI was supposed to cut health care costs. One of its first jobs was charging you more, PwC report shows
AIHealth Care Service
AI was supposed to cut health care costs. One of its first jobs was charging you more, PwC report shows
By Whizy Kim and Tech BrewJune 12, 2026
17 hours ago
Plunge All-in Cold Plunge Review (2026): Expert Tested
HealthDietary Supplements
Plunge All-in Cold Plunge Review (2026): Expert Tested
By Christina SnyderJune 12, 2026
20 hours ago
Redwood Outdoors Duo Sauna Review (2026): Our Honest Experience
HealthDietary Supplements
Redwood Outdoors Duo Sauna Review (2026): Our Honest Experience
By Emily PharesJune 12, 2026
22 hours ago
A person holds an iPhone as someone next to them points at the screen.
EconomyApple iPhone
You can blame America’s plummeting fertility rate on the iPhone, study finds: ‘People are all depressed and alone and doomscrolling’
By Sasha RogelbergJune 12, 2026
1 day ago
fda
HealthTobacco
Why is the FDA approving kid-friendly, fruit-flavored e-cigarettes?
By Matthew Perrone and The Associated PressJune 12, 2026
1 day ago

Most Popular

When SpaceX starts trading, some 'shareholders' will discover they own nothing at all
Investing
When SpaceX starts trading, some 'shareholders' will discover they own nothing at all
By Jim EdwardsJune 12, 2026
1 day ago
Corporate America has been draining the world's water. Matt Damon's new campaign calls on Gap, Starbucks, and Amazon to help give it back
Environment
Corporate America has been draining the world's water. Matt Damon's new campaign calls on Gap, Starbucks, and Amazon to help give it back
By Catherina GioinoJune 9, 2026
4 days ago
Current price of oil as of June 12, 2026
Personal Finance
Current price of oil as of June 12, 2026
By Joseph HostetlerJune 12, 2026
23 hours ago
American taxpayers have spent $33 billion on sports stadiums. They got fewer seats—and higher prices
Success
American taxpayers have spent $33 billion on sports stadiums. They got fewer seats—and higher prices
By Catherina GioinoJune 11, 2026
2 days ago
Analysts expected oil to surge above $200 but China has quietly kept prices half of that—and can’t for much longer
Energy
Analysts expected oil to surge above $200 but China has quietly kept prices half of that—and can’t for much longer
By Sasha RogelbergJune 10, 2026
3 days ago
U.S. energy secretary says 7 million barrels of oil exiting Persian Gulf daily, but Chevron CEO rebuts the claim
Energy
U.S. energy secretary says 7 million barrels of oil exiting Persian Gulf daily, but Chevron CEO rebuts the claim
By Jordan BlumJune 12, 2026
16 hours ago